Physician profile
Charles E Ahner
NPI 1104835628
$2,156.24
in general payments reported to CMS, 2019-2025
33 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $118 · 2021: $315 · 2022: $312 · 2023: $417 · 2024: $313 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.02 | 2019-2025 | |
| Eisai INC. | $291.40 | 2020-2025 | |
| Abbott Laboratories | $183.77 | 2019-2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $107.75 | 2022-2024 | Quviviq |
| Virtus Pharmaceuticals LLC | $80.11 | 2021-2022 | |
| Amgen INC. | $79.49 | 2023-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $73.51 | 2023-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $71.88 | 2024-2025 | Cologuard Collection Kit |
| Acella Pharmaceuticals, LLC | $71.73 | 2023-2025 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.99 | 2019-2023 | Xifaxan |
| Pfizer INC. | $64.43 | 2023-2024 | |
| Romark Laboratories, Lc | $63.45 | 2019-2020 | |
| Allergan, INC. | $59.31 | 2019-2020 | |
| Antares Pharma, INC. | $47.52 | 2019-2022 | |
| Linus Health, INC. | $43.82 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $43.05 | 2025 | Korlym |
| Novo Nordisk INC | $34.96 | 2024-2025 | Ozempic, Rybelsus |
| Acorda Therapeutics, INC | $33.78 | 2023 | Inbrija |
| Clarus Therapeutics INC. | $29.21 | 2021 | |
| Tolmar, INC. | $27.76 | 2024-2025 | Jatenzo |
| Currax Pharmaceuticals LLC | $26.16 | 2022 | |
| Ibsa Pharma INC. | $22.19 | 2020 | |
| Azurity Pharmaceuticals, INC. | $21.57 | 2023 | Adthyza |
| Vertical Pharmaceuticals, LLC | $21.13 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.99 | 2024 | Givlaari |
| Verity Pharmaceuticals INC. | $20.28 | 2025 | Tlando |
| Dexcom, INC. | $17.79 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $16.16 | 2023 | Mounjaro |
| Endo Pharmaceuticals INC. | $15.71 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.24 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.14 | 2023 | Unithroid |
| Arbor Pharmaceuticals, INC. | $13.70 | 2019 | |
| Mml US, INC. | $13.24 | 2024 | Reactiv8 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ahner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.